New alpha-emitting radiopharmaceutical therapy achieves strong responses in advanced prostate cancer
A new alpha-emitting radiopharmaceutical therapy (RPT) for advanced prostate cancer was well tolerated, with no dose-limiting toxicities observed, and showed encouraging signs of antitumor activity, according to a phase 1 trial published in The Journal of Nuclear Medicine's Late-Breaking Fast Track.
Read original article on The Medical News →Related news
-
Researchers develop versatile genetic tool to investigate cell interactions
United Kingdom
-
Hēlo system offers minimally invasive solution for chronic venous thromboembolism
United Kingdom
-
Exploring the potential of immunotherapy in early-stage triple-negative breast cancer
United Kingdom
-
The Midlife Man: Why We Need to Take Men’s Health More Seriously
United States
-
Dismissive consultations leave some autoimmune patients distressed and suicidal
United Kingdom
-
Genetic findings illuminate dental abnormalities and the evolutionary loss of teeth
United Kingdom
-
Millions get GLP-1 drugs through channels insurance records may miss
United Kingdom
-
Immunotherapy combination sets a new standard of care for extensive-stage small cell lung cancer
United Kingdom